购物车
您的购物车当前为空
F9170是一种抗病毒肽,对应HIV-1包膜糖蛋白的789-803氨基酸。它与HIV-1包膜蛋白胞浆尾部的LLP1域结合,并抑制HIV-1 IIIB对MT-2细胞的感染(EC50 = 0.19 µM)。在恒河猴模型的类人猿免疫缺陷病毒(SHIV)感染中,F9170 (3 mg/kg)能降低血浆病毒负荷。

F9170是一种抗病毒肽,对应HIV-1包膜糖蛋白的789-803氨基酸。它与HIV-1包膜蛋白胞浆尾部的LLP1域结合,并抑制HIV-1 IIIB对MT-2细胞的感染(EC50 = 0.19 µM)。在恒河猴模型的类人猿免疫缺陷病毒(SHIV)感染中,F9170 (3 mg/kg)能降低血浆病毒负荷。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 435 | 待询 | |
| 5 mg | ¥ 1,630 | 待询 | |
| 10 mg | ¥ 2,830 | 待询 | |
| 25 mg | ¥ 5,980 | 待询 |
| 产品描述 | F9170, an antiviral peptide derived from the HIV-1 envelope glycoprotein (amino acids 789-803), targets the LLP1 domain in the virus's envelope protein cytoplasmic tail. This interaction inhibits HIV-1 IIIB infection in MT-2 cells, evidenced by an EC50 value of 0.19 µM. Additionally, at a dosage of 3 mg/kg, F9170 significantly lowers plasma viral load in rhesus macaques infected with simian HIV (SHIV). |
| 分子量 | 1983.30 |
| 分子式 | C100H135N21O22.XCF3COOH |
| Smiles | OC(C(F)(F)F)=O.OC(C=C1)=CC=C1C[C@H](NC([C@H](CCCCN)NC([C@H](CC(C)C)NC([C@H](C)NC([C@H](CCC(O)=O)NC([C@@H](NC(CN)=O)CC2=CNC3=CC=CC=C23)=O)=O)=O)=O)=O)C(N[C@@H](CC(C)C)C(N[C@H](C(N[C@@H](CC(N)=O)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@H](C(O)=O)CC4=CNC5=CC=CC=C45)=O)CC6=CC=C(C=C6)O)=O)=O)=O)=O)=O)CC7=CNC8=CC=CC=C78)=O)=O |
| 存储 | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||
| 溶解度信息 | Ethanol: 25 mg/mL (12.61 mM), Sonication is recommended. DMSO: 10 mg/mL (5.04 mM), Sonication is recommended. DMF: 25 mg/mL (12.61 mM), Sonication is recommended. | |||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||
DMSO/Ethanol/DMF
Ethanol/DMF
| ||||||||||||||||||||||||||
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
对于不同动物的给药剂量换算,您也可以参考 更多